

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number  
**WO 01/54677 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/00**
- (21) International Application Number: **PCT/US00/32569**
- (22) International Filing Date:  
30 November 2000 (30.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/178,169 26 January 2000 (26.01.2000) US
- (71) Applicant (for all designated States except US):  
**WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).**
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **PRESSLER, Millton, Lethan [US/US]; 7194 Partridge Way, Saline, MI 48176 (US).**
- (74) Agents: **FEDERMAN, Evan, J.; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 et al. (US).**
- (81) Designated States (national): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/54677 A2**

(54) Title: ACE INHIBITOR-VASOPRESSIN ANTAGONIST COMBINATIONS

(57) Abstract: Combinations of ACE inhibitors and vasopressin antagonists are useful to slow and reverse the process of ventricular dilation, and CHF in mammals.

**THIS PAGE BLANK (USPTO)**

## ACE INHIBITOR-VASOPRESSIN ANTAGONIST COMBINATIONS

## FIELD OF THE INVENTION

This invention relates to compositions comprising a compound which inhibits the actions of angiotensin-converting enzyme and a compound which 5 inhibits the actions of vasopressin enzymes, and the use of such compositions for treating ventricular dilation, heart failure, and cardiovascular pathologies.

## BACKGROUND OF THE INVENTION

Heart failure is a pathophysiologic state in which the heart is unable to 10 pump sufficient blood to meet the metabolic needs of the body. It may be caused by a number of factors affecting the myocardium, some altering systolic function and others interfering with diastolic function and/or both. Ischemic heart disease is the most common cause of heart failure in Western countries. Other common etiologies include: (1) hypertension and hypertrophic cardiomyopathy; (2) dilated 15 cardiomyopathy of known cause (e.g., secondary to diabetes; hypo- or hyperthyroidism; viral or parasitic infection); (3) idiopathic dilated cardiomyopathy; and (4) congenital or acquired valvular disease. Severity of chronic heart failure (CHF) is often categorized by the New York Heart Association (NYHA) Functional Classification system.

Development and progression of CHF is a major unsolved problem. Heart 20 failure is one of the few cardiovascular diseases with increasing prevalence, now afflicting 3 to 4 million persons in the United States of America (USA), a like number in Europe, and 200,000 in Canada. It accounts for tens of billions of dollars of health care expenditure in the USA alone. It is more common with advancing age: 75% of hospitalized CHF patients are over 65 and 50% are over 25 75 years of age. CHF admissions comprise the No. 1 diagnosis-related group (DRG) for the Medicare population; 800,000 to 900,000 hospitalizations in the USA per year are related to CHF decompensation. The prognosis remains poor despite increasing understanding of mechanisms and new treatments. Around

-2-

465,000 new cases of heart failure develop in the USA annually and there are over 250,000 deaths. Fifty percent to 60% of patients are dead within 5 years of diagnosis; 1-year mortality is approximately 40% to 50% for those with severe functional impairment. Roughly 20% of the heart failure population  
5 (600,000 persons in the USA) suffers from severe (NYHA Functional Class III/IV) CHF.

Chronic treatments for CHF include digoxin, diuretics, angiotensin converting enzyme (ACE) inhibitors, the combination of hydralazine and isosorbide dinitrate, and  $\beta$ -blockers, specifically carvedilol. Acute medical therapies for heart failure also include inotropic agents (e.g., dobutamine, milrinone, amrinone), parenteral loop diuretics, and oxygen. Several landmark studies in the 1980s and early 1990s (e.g., CONSENSUS; SOLVD) showed that ACE inhibitors could lengthen survival and reduce the number of hospitalizations of patients with symptomatic CHF (*N. Eng. J. Med.*, 1987;316:1429-1435; and 1991;325:293-302). Even patients with asymptomatic left ventricular (LV) systolic dysfunction were found to benefit by treatment with an ACE inhibitor (SOLVD prevention study). The postulated mechanism is that ACE inhibitors prevent or reduce the upregulation of the renin-angiotensin system (RAS). Unfortunately, no currently available ACE inhibitor is completely effective in halting the progression of heart failure. The majority of CHF patients given optimal treatment with an ACE inhibitor still progress to intractable pump failure or suffer sudden death. As a result, therapies have been directed at other factors associated with progression of heart failure. Increased sympathetic tone and plasma catecholamines are believed to play a role. The degree of functional impairment is roughly correlated with magnitude of sympathetic upregulation.  
20 Several  $\beta$ -blockers have been investigated albeit with mixed results. Carvedilol, a nonselective  $\beta$ -blocker, has been shown to lessen combined CHF morbidity and mortality in chronic mild to moderate heart failure. However, some patients decompensate during initiation of drug therapy, and its use is not approved in patients with acute heart failure. Furthermore, patients treated with carvedilol plus 25 an ACE inhibitor continue to progress inexorably toward death. Patients with 30

-3-

advanced heart failure have limited medical options even though ACE inhibitors and carvedilol are useful adjuncts.

Heart failure may be precipitated acutely by the loss of viable myocardium, but its gradual progression over many years involves many interdependent factors: catecholamines and other hormonal factors (e.g., 5 angiotensin II [Ang II]; aldosterone; arginine vasopressin [AVP]; Endothelin-1 [ET-1]; Atrial Natriuretic Factor [ANF]) are thought to contribute to the pathophysiology of LV enlargement and myocardial "remodeling" (Pauleur, *Am. J. Cardiol.*, 1994;73:36C-39C). The benefits of ACE inhibition have pointed to the key role of the renin-angiotensin system (especially Ang II) in LV dilation and 10 heart failure development. However, the progression of heart failure may not involve the same underlying mechanism throughout its course. One set of factors may play a primary role in the onset and early progression of ventricular dysfunction, other substances in the middle phase of symptoms and events, and different factors in the terminal phases of the disease. Furthermore, the benefits 15 and risks of therapeutic interventions may vary with the severity of heart failure. Patients with severe heart failure are most prone to hospitalization and most restricted in their functional capacity. These are the patients that become unresponsive to ACE inhibitors. Of note, serum sodium concentration is an independent prognostic factor for outcome of patients with severe CHF. 20 Hyponatremic patients have a much higher mortality and frequently have serial admissions for heart failure decompensation. These observations suggest that AVP, the neurohormone responsible for regulation of serum osmolality, may be a key factor in progression of heart failure in severely compromised patients..

25 AVP, a neuropeptide hormone, is synthesized in the hypothalamus, stored in the posterior pituitary, and released into the circulation after activation of neurosecretory cells. There are 2 AVP receptor subtypes. The V<sub>1A</sub>-subtype mediates contraction in blood vessels and platelet aggregation. V<sub>1</sub> receptors are also involved in the stimulating effect of AVP on adrenocorticotropic hormone 30 (ACTH) secretion. The V<sub>2</sub> receptor is coupled to aquaporine channels in the human kidney and modulates water clearance.

-4-

I have now discovered that compounds which inhibit ACE can be used in conjunction with compounds which inhibit vasopressin enzymes to achieve surprisingly good results in treating CHF and related cardiovascular diseases like ventricular dilation, cardiac inefficiency, and hypertension.

5

#### SUMMARY OF THE INVENTION

10


This invention provides a composition comprised of an ACE inhibitor and a vasopressin antagonist. Any ACE inhibitor can be employed in this invention. In a preferred embodiment, the ACE inhibitor is selected from captopril, enalapril, enalaprilat, lisinopril, ramipril, zofenopril, ceroanapril, alacepril, benazepril, delapril, pentopril, quinapril, quinaprilat, moexipril, rentiaprile, quinapril, spirapril, cilazapril, perindopril, and fosinopril.

15

The vasopressin antagonist to be employed is any chemical compound that is effective in inhibiting the biological activity of any arginine vasopressin or antidiuretic hormone. Numerous compounds are known to be vasopressin antagonists, and any of such compounds can be utilized in the composition of this invention.

20

In a preferred embodiment, the vasopressin antagonist to be utilized is a condensed benzazepine such as those described in U.S. Patent No. 5,723,606, incorporated herein by reference. In a further preferred embodiment, the vasopressin antagonist is an imidazo benzazepine of the Formula I



I

wherein R and R<sup>5</sup> are hydrogen or lower alkyl;


-5-

R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> independently are hydrogen, halo, lower alkyl, lower alkoxy, amino, alkylamino, or dialkylamino; and

R<sup>4</sup> is hydrogen, phenyl or substituted phenyl, and pharmaceutically acceptable salts thereof.

5 An especially preferred vasopressin antagonist to be used in accordance with this invention is Conivaptan, which is N-[4-(2-methyl-,4,5,6-tetrahydromidazo[4,5-d][1]benzazepin-6-ylcarbonyl)phenyl]biphenyl-2-carboxamide hydrochloride. Conivaptan is also referred to as CI-1025, as well as YM087, and has the structural formula below

10



Other vasopressin antagonists that can be employed accordingly to this invention include the benzoheterocyclic compounds described in U.S. Patents No. 5,258,510, incorporated herein by reference. Preferred compounds from this class to be used herein include the following:

15

5-Dimethylamino-1-[4-(2-methylbenzoylamino)-benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine;

5-Dimethylamino-1-[2-chloro-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine;

5-Methylamino-1-[2-chloro-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine;

5-Cyclopropylamino-1-[2-chloro-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine;

5-Cyclopropylamino-1-[2-chloro-4-(2-chlorobenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine;

20

-6-

5-Dimethylamino-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-  
2,3,4,5-tetrahydro-1H-benzazepine;  
5-Dimethylamino-1-[2-methoxy-4-(2-methylbenzoylamino)benzoyl]-  
1,2,3,4-tetrahydroquinoline;  
5-Chloro-5-methylamino-1-[4-(2-methylbenzoylamino)benzoxyl]-2,3,4,5-  
tetrahydro-1H-benzazepine; and  
7-Chloro-5-methylamino-1-[4-(2-chlorobenzoylamino)benzoxyl]-2,3,4,5-  
tetrahydro-1H-benzazepine.

Other vasopressin antagonists that can be employed according to this  
10 invention include those described in U.S. Patent Nos. 5,225,402; 5,258,510;  
5,338,755; 5,719,155; and 5,710,150, all of which are incorporated herein by  
reference. Specific vasopressin antagonists include YM471, OPC-31260,  
OPC-21268, OPC-41061, SR-121463, SR-49059, VPA-985, CL-385004,  
FR-161282, JVT-605, VP-339, WAY-140288, and the like.

15 The invention also provides a method for treating CHF, ventricular  
dilation, and hypertension by administering to a mammal in need of treatment an  
effective amount of the combination of an ACE inhibitor and a vasopressin  
antagonist.

#### BRIEF DESCRIPTION OF FIGURES

20 Figure 1 shows the reduction in baseline pulmonary capillary wedge  
pressure (PCWP) caused by various doses of conivaptan in patients receiving an  
ACE inhibitor.

Figure 2 shows the reduction in right atrial pressure (RAP) caused by  
various doses of conivaptan in patients receiving an ACE inhibitor.

#### 25 DETAILED DESCRIPTION OF THE INVENTION

The ACE inhibitors to be employed in the compositions of this invention  
are well-known in the art, and several are used routinely for treating hypertension.

-7-

For example, captopril and its analogs are described in U.S. Patent Nos. 5,238,924 and 4,258,027. Enalapril, enalaprilat, and closely related analogs are described in U.S. Patent Nos. 4,374,829; 4,472,380; and 4,264,611. Moexipril, quinapril, quinaprilat, and related analogs are described in U.S. Patent Nos. 4,743,450 and 5 4,344,949. Ramipril and its analogs are described in U.S. Patent Nos. 4,587,258 and 5,061,722. All of the foregoing patents are incorporated herein by reference for their teaching of typical ACE inhibitors which can be utilized in combination with a vasopressin antagonist according to this invention. Other ACE inhibitors which can be utilized include fosinopril, fasidotril, glycopril, idrapril, imidapril, 10 mixanpril, perindopril, spirapril, spiraprilat, temocapril, trandolapril, zofenopril, zofenoprilat, utilapril, sampatrilat, SA 7060, DU 1777, BMS 186716, and C 112. All of the references cited herein are incorporated by reference for their teaching 15 of components of the now claimed combinations.

The compositions of this invention will contain an ACE inhibitor and a vasopressin antagonist in a weight ratio of about 0.05:1 to about 1000:1, and typically about 1:1 to about 500:1, and ideally about 1:1 to about 5:1. A typical composition, for example, will have 20 mg of quinapril hydrochloride and about 10 mg of conivaptan. All that is required is that amounts of each component are used which are effective to inhibit or reverse CHF, ventricular dilation, or 20 hypertension. The compounds can be administered separately to a patient to effect treatment according to this invention.

As used herein, "patient" means a mammal suffering from a cardiovascular disorder such as CHF and in need of treatment. Patients include humans and animals such as dogs, cats, and sheep. The method of this invention is practiced by administering an effective amount of an ACE inhibitor and a vasopressin antagonist to a patient.

An "effective amount" as used herein is the individual quantities of ACE inhibitor and vasopressin antagonist that are routinely used in clinical treatment of hypertension and other cardiovascular disorders. Typical effective amounts will be 30 about 5 to about 500 mg/kg of ACE inhibitor, and about 1 to about 100 mg/kg of vasopressin antagonist. The "effective amount" is that quantity that gives a positive effect in treating the CHF, for example, by causing a reduction in PCWP or in RAP. The precise dosage that is effective according to this invention will be

-8-

determined by the attending medical practitioner, taking into account the specific ACE inhibitor and vasopressin antagonist being administered, the particular condition of the patient being treated, the duration of the treatment and severity of the disease, and such other factors routinely considered when practicing sound medical judgment.

The combination of an ACE inhibitor with a vasopressin antagonist is synergistic in its ability to treat cardiovascular pathologies such as CHF, as well as hypertension, and left ventricular systolic dysfunction.

Terms used in this specification have the following meanings:

10	CHF	Congestive Heart Failure
	NYHA	New York Heart Association
	CI	Cardiac Index
	PCWP	Pulmonary Capillary Wedge Pressure
	SBP	Systolic Blood Pressure
15	PVR	Pulmonary Vascular Resistance
	SVR	Systemic Vascular Resistance
	RA	Right Atrial Pressure
	PAs	Pulmonary Artery Systolic Pressure
	PAd	Pulmonary Artery Diastolic Pressure
20	DBP	Diastolic Blood Pressure
	MAP	Mean Arterial Pressure
	LV	Left Ventricular
	CAD	Coronary Artery Disease
	ALT	Alanine Aminotransferase
25	AST	Aspartate Aminotransferase
	Alk Phos	Alkaline Phosphatase
	LV-EF	Left Ventricular Ejection Fraction
	MuGA	Multi-Gated Radionuclide Ventriculogram
	ACE	Angiotensin Converting Enzyme
30	Cr	Serum Creatinine
	BUN	Blood Urea Nitrogen
	WBC	White Blood Cells
	Hgb	Hemoglobin

-9-

	ULN	Upper Limit of Normal
	HR	Heart Rate
	CRF	Case Report Form
	COPD	Chronic Obstructive Pulmonary Disease
5	FVC	Forced Vital Capacity
	FEV <sub>1</sub>	Forced Expiratory Volume in 1 Second

#### EXAMPLE 1

The following studies establish the clinical efficacy of YM087 and combinations of ACE inhibitors and vasopressin antagonists.

10 Preclinical pharmacologic studies have demonstrated potent binding of YM087 conivaptan to AVP receptors and antagonism of the vascular and renal effects of AVP. YM087 has high affinity for V<sub>1A</sub>- and V<sub>2</sub>-receptors with pKi (negative log of the binding inhibition constant) of 8.20 for human V<sub>1A</sub>-receptors and 8.95 for human V<sub>2</sub>-receptors expressed in COS-1 cells.

15 **Clinical Pharmacology**

YM087 given orally to rats antagonizes the AVP-induced pressor response (V<sub>1A</sub> antagonism) in a dose-related manner, with the dose that reduced the AVP response by 50% (ID<sub>50</sub>) being 0.32 mg/kg; ID<sub>50</sub> for a similar experiment using intravenous (IV) YM087 in dogs was 0.026 mg/kg. In conscious dogs, oral YM087 (0.03 to 0.3 mg/kg) increased urinary output (V<sub>2</sub> antagonism) and reduced urinary osmolality (from 1500 to <100 mOsm/kg H<sub>2</sub>O) in a dose-related manner. Unlike furosemide, YM087 has little or no effect on urinary sodium (Na) or potassium (K) excretion. In dogs with heart failure induced by rapid right ventricular pacing, intravenous administration of YM087 (0.1 mg/kg) significantly improved the depressed cardiac function and produced a water diuresis.

20 Oral absorption of YM087 is rapid (peak concentrations reached between 0.5 to 1 hour in the rat and dog, respectively) and occurs predominantly in the small intestine. There is a marked food effect with absorption reduced by >50% in dogs after a meal. The elimination half-life is 1 hour in rats and 2 hours in dogs.

25 Mass balance studies show the majority of radioactive tracer excreted in the feces.

-10-

The preclinical toxicologic potential of YM087 has been extensively evaluated, and all findings were evaluated for relevance to human risk assessment and impact on clinical trial design. Findings of potential concern were bone marrow changes in dogs and effects on fertility in rats.

5 Histopathologic changes in bone marrow were observed in both 2- and 13-week oral studies in dogs with systemic exposures 28- to 87-fold higher than the maximum anticipated human exposure. Decreased peripheral erythrocyte, leukocyte, and/or platelet counts occurred in affected dogs in the 13-week study. Bone marrow and peripheral blood changes were reversible.

10 YM087 did not affect reproductive performance of male rats. In the 13-week, repeated oral dose study in rats, more females at 10 mg/kg were in diestrus or proestrus and fewer were in estrus than in controls, and uterine weights were decreased at all doses; associated systemic exposures were 0.06- to 3.2-fold the maximum anticipated human exposure. In the female fertility study in rats, reduced fertility index, increased implantation loss, and decreased live fetuses were observed in females given 100 mg/kg orally for 2 weeks prior to mating with untreated males. Effects on estrous cycle and fertility in female rats may be related to alterations in serum hormone levels resulting from pharmacologic activity of YM087. YM087 was not teratogenic in rats or rabbits.

15 20 Other drug-related effects, including diuresis and hepatocellular hypertrophy, were of less concern due to the nature of the effects or the high exposures at which the effects occurred compared to exposures anticipated in clinical trials.

25 YM087 was not mutagenic in bacteria, and was not clastogenic in human lymphocytes in vitro or in bone marrow of rats. No toxicity was observed in 4-week, IV studies with the glycerin formulation at maximum achievable doses, 2.5 mg/kg in rats and 2 mg/kg in dogs.

30 In summary, toxicological findings of potential concern for human risk assessment were reversible effects on bone marrow in dogs and reversible effects on estrus cycle and decreased fertility in rats. Findings in bone marrow were observed at exposures in excess of 23 times exposure expected in humans given the maximum dose of 120 mg once daily (QD), while effects on estrus cycle occurred at exposures from 0.05- to 3-fold the expected human exposure at

-11-

120 mg QD. Other drug-related findings in toxicology studies were considered secondary to pharmacologic activity or a functional adaptation to exposure to YM087.

5 YM087 has been given to approximately 250 healthy subjects who participated in a total of 15 Phase 1 studies (8 in Japan and 7 in Europe). Subjects taking oral medication received either a single dose of YM087 (dose range 0.2 through 120 mg) QD or 30 or 120 mg YM087 administered as a divided dose twice daily (BID). Subjects received YM087 as a single IV injection once daily over a dose range of 0.2 to 250 µg/kg or up to a maximum of 50 mg.

10 Inhibition of AVP-induced platelet aggregation (evidence of V<sub>1A</sub> antagonist activity) was seen among subjects who received YM087 at 20 mg/day orally or 2.5 mg IV. Total inhibition of AVP-induced dermal vasoconstriction was observed among subjects who received YM087 50 mg IV.

15 Normal subjects have demonstrated aquaesthetic action (evidence of V<sub>2</sub>-receptor antagonism) accompanied by a decrease in urine osmolarity starting at 15 mg oral or 50 µg/kg IV. At higher doses aquaesthetic effects were more pronounced and at 120 mg QD or 60 mg BID given orally or 50 mg given IV were considered too uncomfortable in normal subjects to be tolerable. YM087 at IV doses up to 250 µg/kg and 50 mg/day increased urine production rate for up to 20 3 and 6 hours postdosing, respectively.

20 Under fasting conditions, YM087 is rapidly absorbed, time to maximum plasma concentration (t<sub>max</sub>) being reached at around 1 hour. The mean oral bioavailability of a 60-mg dose is 44% under fasting conditions; bioavailability is decreased after intake with food. A high-fat breakfast reduced bioavailability of 25 single 15- to 90-mg doses of YM087 to 43% to 59% of the fasted value, and peak plasma levels were reduced to 24% to 54% of the fasting value. Oral YM087 demonstrated a nonlinear pharmacokinetic profile. Repeated BID oral doses of YM087, 60 mg, result in unexpectedly high plasma levels after the second dose, possibly caused by reduced first-pass metabolism. YM087 displays 30 2 compartment pharmacokinetics, with an elimination half-life of 4 to 5 hours. Elderly subjects have a similar elimination half-life as healthy, young volunteers.

-12-

The pharmacokinetics of orally administered YM087 (20 mg) were not affected when combined with either 0.5 mg IV digoxin or 25 mg oral captopril (each given as a single dose).

### Safety

5 Among approximately 250 subjects treated, no major safety concerns were identified. One patient with severe CHF who received YM087 80 mg/day for 4 days experienced a generalized tonic clonic seizure, which the investigator could not exclude as related to study drug. The most frequent adverse events regardless of treatment association were mild or moderate thirst and mild headache. Other 10 adverse events included flushes, a sensation of cold extremities, abdominal complaints, abnormal stools, syncope, dizziness, palpitations, and postural hypotension. Three subjects who received YM087 and one subject who received placebo developed minor, reversible leukopenia. No drug-related trend was observed in biochemical or hematological laboratory parameters. At higher doses, 15 urinary osmolarity decreased and plasma osmolarity increased with or without an increase in plasma sodium. These observations were considered related to antagonism of V<sub>2</sub> receptors and not a safety concern. Vital signs (blood pressure and heart rate) were unaffected by YM087.

### EXAMPLE 2


#### 20 ACE + Vasopressin Antagonists in CHF

This trial is a double-blind, placebo-controlled study of the intravenous dose response of YM087 on cardiopulmonary hemodynamics in 142 patients with Class III/IV heart failure. These patients have advanced CHF/LV dysfunction. Patients must be receiving background therapy of diuretics, ACE inhibitors, and 25 optionally digoxin and/or β-blocker; patients will be stratified as to whether they are receiving concomitant β-blocker treatment. Eighty-five percent of the patients in this study received an ACE inhibitor and YM087. Patients should take their daily dose of concomitant heart failure medications within 2 hours of catheter insertion. No additional doses of background heart failure medications should be 30 administered during the study treatment phase. After insertion of a balloon-floatation pulmonary artery catheter, serial measurements will be obtained over an

-13-

8- to 18-hour baseline and stabilization period. Patients meeting baseline eligibility criteria ( $CI \leq 2.6 \text{ L/min/m}^2$ ;  $PCWP \geq 16 \text{ mmHg}$ ) after catheter stability is assured will be administered an IV dose (30-minute infusion) of YM087 or placebo and monitored for the subsequent 12 hours. The mean baseline PCWP in this study group was 24.2 mmHg. The mean baseline CI was 2.1  $\text{L/min/m}^2$ .  
 5 Hemodynamic parameters and vital signs will be measured at baseline during the 2 hours prior to drug administration and 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours after start of the IV infusion. A urethral cathether will be placed and urine output will be measured hourly for 2 hours prior until 12 hours poststudy drug  
 10 administration. Fluid intake will be restricted to 250 mL every 2 hours (except at time of IV infusion) from time of insertion of Swan-Ganz catheter and throughout the treatment period. YM087 plasma levels will be determined at 1, 3, and 8 hours posttreatment. Serum electrolytes, BUN, creatinine, and serum osmolality will be measured at baseline and 4 and 12 hours posttreatment. Clinical laboratory and  
 15 vasopressin plasma levels will be measured at baseline and 12 hours postdrug administration. A numeric rating scale for assessing dyspnea will be administered at baseline and 12 hours after study drug administration. The dosing and analysis schedule used in this study is shown in Table 1.

TABLE 1



-14-

#### Screening and Baseline Phase (10-20 Hours)

- This phase allows the investigator to evaluate patients who may qualify for entry into the treatment period and to assess baseline values for a number of study parameters. An informed consent must be signed. A medical history, physical examination, and assessment of NYHA functional class will be done. Clinical laboratory parameters will be measured. If left ventricular ejection fraction (LV-EF) has not been measured during the previous 3 months, the patient will undergo radionuclide, contrast ventriculography, or 2-dimensional echocardiography to measure LV-EF.
- 5 Patients must remain on stable doses of background heart failure medications throughout the baseline and treatment phase. Patients should take a dose of their concomitant heart failure medications within 2 hours of Swan-Ganz catheter insertion. No additional dose of background medications should be administered during the study treatment phase. After insertion of a balloon-floatation pulmonary artery catheter, several measurements of hemodynamic parameters will be obtained over a 8- to 18-hour baseline and stabilization period.
- 10 Patients meeting baseline eligibility criteria ( $CI \leq 2.6 \text{ L/min/m}^2$ ; PCWP  $\geq 16 \text{ mmHg}$ ) on successive readings at least 30 minutes apart during 2 hours prior to study drug administration will enter the treatment phase. Additional measurements of hemodynamic parameters over a larger baseline period ( $\geq 2 \text{ hours}$ ) may be required to meet the reproducibility criteria. The 2 successive measurements of PCWP and CO must be  $\pm 10\%$  and  $\pm 15\%$ , respectively, of the mean. Patients should fast 6 hours prior to baseline measurements and must remain fasting for the first 6 hours of the 12-hour treatment phase.
- 15
- 20
- 25 Patients who qualify for entry will have blood drawn for a baseline assessment of clinical laboratory and vasopressin plasma levels. A urethral cathether should be placed and urinary output measurements will be obtained hourly for  $\geq 2$  hours prior to study drug administration and thereafter during the treatment phase. Hemodynamic measurements should be obtained at least 30 minutes after insertion of the urethral catheter. Fluid intake will be restricted to 250 mL every 2 hours (except at time of IV infusion) from time of insertion of Swan-Ganz catheter and throughout treatment period. Vital signs will be assessed
- 30

-15-

at least every 4 hours. A numeric rating scale for assessing dyspnea will be administered within 1 hour of study drug administration.

**Treatment Phase (12 Hours):**

Patients meeting baseline eligibility criteria will be randomized within an hour to receive double-blind IV bolus dose, administered over 30 minutes, of placebo or 1 of 3 doses of YM087 (10, 20, or 40 mg) in a 1:1:1:1 ratio. Patients should refrain from taking concomitant heart failure medications during the 12-hour treatment period. Patients will be stratified as to whether they are receiving concomitant treatment with a  $\beta$ -blocker. Hemodynamic parameters (cardiac output, intrapulmonary and systemic pressures) and vital signs will be measured at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after start of the IV infusion. Clinical laboratory and vasopressin plasma levels will be measured 12 hours postdose. YM087 plasma levels will be determined at 1, 3, and 8 hours posttreatment. Serum electrolytes, BUN, creatinine, serum osmolality will be measured at 4 and 12 hours posttreatment. Hourly urine output measurements will be obtained during the entire 12-hour treatment phase. The numeric rating scale for assessing dyspnea will be administered 12 hours postadministration of study medication.

**Posttreatment Phase (24-48 Hours) After Administration of Study**

**Medication:**

Patients must return for an outpatient follow-up visit at least 24 to 48 hours after administration of study medication. Patients will be followed for clinical assessment of adverse events. Clinical laboratory parameters will be measured. Background heart failure medications will be readjusted if necessary for safety/tolerance of the patient.

**25 STUDY POPULATION**

All patients enrolled into this study will have NYHA Class III/IV heart failure due to systolic LV dysfunction.

-16-

#### Source and Number of Patients

A total of 142 patients (35 per treatment group) will be enrolled at 20 study centers. Each site is expected to enroll 6 to 8 patients. Enrollment is competitive and will stop when the study is complete.

#### 5 Patient-Selection Criteria

##### Inclusion Criteria

Patients acceptable for inclusion into the study must meet the following criteria:

- Males or females 18 to 80 years of age; females must be postmenopausal, surgically sterilized, or practicing a suitable method of birth control so that in the opinion of the investigator, they will not become pregnant during the study;
- Symptomatic heart failure with Class III/IV functional impairment by NYHA criteria;
- Current therapy for heart failure consisting of at least 1 month duration of an ACE inhibitor, loop diuretic, and optionally digoxin and/or  $\beta$ -blocker;
- Cardiac index  $\leq 2.6$  L/min/m<sup>2</sup>; and PCWP  $\geq 16$  mmHg on successive readings at least 30 minutes apart prior to study drug administration; and
- Signed informed consent.

#### 20 Exclusion Criteria

Presence of any of the following conditions will exclude the patient from being eligible for study:

- Breast feeding or pregnant;
- Patients with supine systolic blood pressure  $< 95$  mmHg or uncontrolled hypertension;
- Patients with more than 2+ edema (above the knee);
- Uncontrolled symptomatic brady- or tachyarrhythmias (e.g., sinus arrest; second-degree Mobitz type II) or third-degree AV block; atrial fibrillation or flutter; frequent runs of ventricular tachycardia); patients with dual chamber

-17-

- pacemakers and/or implantable defibrillators are eligible, if the device has been implanted >60 days prior to screening;
- Unstable angina pectoris and/or acute myocardial infarction within 1 month of baseline;
  - 5 • Patients with severe COPD (FVC ≤1.5 L; FEV<sub>1</sub> ≤1.0 L) or primary pulmonary hypertension;
  - Patients with significant uncorrected primary valvular disease or uncorrected congenital heart disease; for example, aortic stenosis (AVA <0.8 cm<sup>2</sup>), mitral stenosis (MVA <1.2 cm<sup>2</sup>/m<sup>2</sup>), severe valvular insufficiency requiring valve replacement;
  - 10 • Patients with obstructive cardiomyopathy;
  - Patients with active myocarditis, constrictive pericarditis, untreated hypothyroidism or hyperthyroidism, adrenal insufficiency, active vasculitis due to collagen vascular disease, or other correctable nutritional or metabolic causes for heart failure;
  - 15 • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations >3 times the upper limit of normal (ULN) reference range and/or bilirubin ≥2 mg/dL;
  - Patients with significant renal impairment; serum creatinine >2.5 mg/dL or creatinine clearance <30 mL/min;
  - 20 • Serious hematological diseases (e.g., severe anemia, Hgb <10 g/dL; leukopenia, white blood cell [WBC] <4000/µL);
  - Active cancer within 5 years of screening for this study (exclusive of localized skin cancer or localized prostate cancer);
  - 25 • Patients on continuous and/or daily doses of IV inotropic drugs (e.g., dobutamine; dopamine, milrinone, amrinone, etc) or parenteral vasodilators (e.g., nitroprusside; nitroglycerin) within 7 days of screening;
  - Clinical evidence of digitalis toxicity;

-18-

- Current illicit drug use or alcoholism;
- Any concurrent illness which, in the opinion of the investigator, may interfere with treatment, evaluation of safety, and/or efficacy;
- Participation in another clinical trial of an investigational drug (including placebo) within 30 days of screening for entry into the present study; or
- Inability to understand and sign the Informed Consent to participate in this study.

#### **Prohibited/Allowable Medications or Precautions**

To minimize confounding factors and bias in interpreting results related to potential cardiac changes not associated with natural progression of CHF, concurrent heart failure medications should be held stable throughout the treatment phase of the study. Changes in concurrent medications can and should be made where issues of patient safety are evident.

Nonsteroidal anti-inflammatory agents (NSAIDS) are discouraged due to their inhibitory effects on renal function.

Permitted medications include those used to treat coronary artery disease (CAD), hypertension, diabetes, hyperlipidemia, and CHF. Heart failure medications can include ACE inhibitors, diuretics, digoxin, β-blocker, and intermittent oxygen. No other parenteral vasodilators (e.g., nitroprusside, nitroglycerin) nor initiation of inotropic agents will be allowed. Chronic low dose ( $\leq 300$  mg QD) amiodarone is permissible but not sotalol, dofetilide or other Class III antiarrhythmic agents. Calcium channel blockers with negative inotropic effects (e.g., verapamil, diltiazem) are prohibited.

Patients enrolled in this study cannot be participating in any other ongoing protocol studying the effects of investigational medications.

#### **Meals and Fluid Intake**

Patients should fast at least 6 hours prior to baseline hemodynamic measurements and must remain fasting during the first 6 hours of the 12-hour treatment phase.

-19-

Fluid intake will be restricted to 250 mL every 2 hours (except at time of IV infusion of study medication) from time of insertion of Swan-Ganz catheter and throughout the treatment period.

## STUDY METHODOLOGY

### 5 Efficacy Parameters

#### Primary Efficacy Parameter

Peak change from last baseline measurement in PCWP at 3 to 6 hours after start of study medication infusion as compared to placebo. Other characteristics of response profile (area under the PCWP/time curve) are defined in statistical analysis section of the protocol.

#### Secondary Efficacy Parameters

- Peak change from last baseline measurement at 3 to 6 hours after start of study medication infusion as compared to placebo in:
  - Cardiac index (CI)
  - Pulmonary vascular resistance (PVR)
  - Systemic vascular resistance (SVR)
- Other characteristics of response profile (CI, PVR, SVR) are defined in the statistical analysis section of the protocol (area under the curve [AUC]).
- Changes in urine output over time as compared to baseline.
- Descriptive statistics for RA, PAs, PAd, BP, HR will also be performed.
- Change from baseline in numeric rating scale for assessing dyspnea at 12 hours after administration of study medication.

### Safety Assessments

- Hemodynamic Parameters: Boundary values for reduced cardiovascular performance are (expressed as changes from baseline demonstrated on 2 successive readings  $\geq$ 30 minutes apart): (a) >25% decrease in CI from baseline; (b)  $\geq$ 6 mmHg rise in PCWP above baseline; and (c) systolic arterial BP (SBP) <80 mmHg or >10 mmHg fall in SBP associated with presyncopal symptoms;

-20-

- Changes in serum electrolytes;
- Clinical laboratory measures including renal function (BUN and creatinine), liver function tests (ALT, AST, Alk Phos, bilirubin), hematological parameters (WBC, neutrophils);
- 5     • Adverse events;
- Changes in urine output over time.

#### Pharmacokinetic/Pharmacodynamic Analysis

Plasma concentrations of YM087 will be measured at 1, 3, and 8 hours after start of IV infusion of study medication using a validated LC/MS/MS method. Assay sensitivity, specificity, linearity, and reproducibility will be determined before analysis of samples.

The relationship between the primary efficacy parameters and plasma concentrations of YM087 including the interindividual variability will be evaluated using appropriate pharmacostatistical methods.

#### 15     Neurohormonal Assessments

Vasopressin plasma levels will be measured at baseline and 12 hours after start of IV infusion of study medication using standard methods.

#### Dosing Procedure

YM087 sterile injection will be added to a 50-mL bag containing D5W. Table 2 specifies the amount of YM087 for injection to dilute into D5W in order to achieve the desired dose. The contents of the bag will be administered to the patients via a pump infusion system (e.g., IMED™, IVACT™) over 30 minutes.

**TABLE 2. YM087 Dose Administration**

Dose (mg)	Volume of YM087 (mL)	Volume of D5W added (mL)	Total Volume in Bag (mL)	Concentration (mg/mL)	Infusion Rate Over 30 Minutes (mL/min)
10	2	8	60	0.167	2
20	4	6	60	0.333	2

-21-

40	8	2	60	0.667	2
----	---	---	----	-------	---

---

## STATISTICAL ANALYSIS AND RATIONALE

### Power and Sample Size

For this study, a total of 140 patients will be considered with 35 patients in each of the 4 treatment groups (placebo, 10, 20, and 40 mg). The power to detect a difference of 3 mmHg in the PCWP peak change from baseline within 3 to 6 hours after treatment administration, between placebo and any of the 3 active treatments, was determined using the formula for the power of the t-test. Adjustment for multiple comparisons with placebo was performed using Dunnett's approach (Dunnett, *Biometrics*, 1964;20:482-491). Assuming a 15% dropout rate, an overall error rate of 0.05 two-sided, and a standard deviation of 3 mmHg for the PCWP peak change, the power to detect a difference of 3 mmHg between placebo and any of the YM087 groups is 93.6%. However, if a standard deviation of 4 mmHg is assumed, the power becomes 71.1%.

### Efficacy Parameters

Hemodynamic data in clinical trials of congestive heart failure is usually assessed by evaluating the differences in change from baseline to peak response among treatment groups. Generally, peak response is defined as an average of measurements taken at prespecified hours (e.g., at 2, 3, and 4 hours).

For this study, hemodynamic efficacy parameters of PCWP, CI, SVR, and PVR will be evaluated in terms of their response profile. The response profile will be assessed in terms of peak change, and AUC delimited by the parameter change from baseline and measurement times. The peak change is defined as the maximum change from baseline, within the 3 to 6 hours after treatment administration, in the hemodynamic parameter of interest. The baseline value is considered the last acceptable measurement taken before treatment administration. The AUC will be determined using the "linear trapezoidal rule", by which areas of each trapezoid delimited by: 2 points on the graph of change from baseline against time, perpendiculars from the points to the X-axis, and the X-axis are summed up to get AUC. If measurements are missing at certain times, the AUC will be

-22-

calculated using all other available observations. Dose response over the treatment groups will be assessed for selected measures.

The primary efficacy parameter for this study is peak change from baseline in PCWP. The secondary parameters are peak change from baseline in CI, SVR, 5 and PVR. Changes in RA and PA pressures also will be characterized. In addition, changes in urine output will be characterized.

#### Analysis of the Primary Efficacy Parameter

An analysis of covariance (ANCOVA) model will be used as the primary 10 analysis to compare each of the YM087 doses with placebo in terms of peak change in PCWP. The model will include effects due to treatment, center, an indicator variable for the presence or absence of  $\beta$ -blocker therapy, and possibly the baseline value as a covariate. Treatment-by-center and treatment-by-baseline interactions will be investigated. All randomized patients that have a baseline measurement and at least one follow-up measurement will be considered for this 15 analysis. If there is only one observation within 3 to 6 hours then the peak change will be calculated using that observation and the baseline value. If there are no measurements in the 3 to 6 hour window, the last measurement prior to hour 3 will be carried forward and used to calculate peak.

A secondary analysis of the AUC will be conducted to support the primary 20 analysis. For the area under the PCWP change from baseline and time curve, the analysis will be conducted using ANCOVA in a similar manner as described for the primary analysis. The model will include effects due to treatment, center, an indicator variable for the presence or absence of  $\beta$ -blocker therapy, and possibly the baseline value as a covariate. Treatment-by-center and treatment-by-baseline 25 interactions will be investigated. All randomized patients that have a baseline and at least one follow-up measurement will be considered for this analysis.

In order to claim positivity, results from the primary analysis for peak 30 change in PCWP should be significant at the  $\alpha$  level corresponding to 0.049 using Dunnett's approach, or results from the secondary analysis of AUC at the 0.001 level. A supportive secondary trend analysis for dose response will also be performed. Also, repeated measures ANCOVA will be performed for selected measurements of the response profile.

-23-

Analysis of the Secondary Efficacy Parameters

The primary analysis for the secondary efficacy parameters of CI, SVR, and PVR will be performed using ANCOVA as described for the primary efficacy parameter, to compare the treatment groups with placebo in terms of their peak change from baseline. Patients will be considered for this analysis according to the criteria described for the primary parameter. The significance levels will be adjusted for multiple comparisons with placebo using Dunnett's method.

Analysis of the AUC and trend analysis will be considered supportive, and conducted in the same manner as described for the primary parameter. Repeated measures ANCOVA will be performed for selected measurements of the response profile. All randomized patients with a baseline and at least one follow-up measurement will be considered.

The secondary parameter of urine output will be summarized at baseline, and each collection time. In addition, a numeric rating scale will be used for assessing dyspnea. The corresponding change from baseline for these parameters will be summarized. Descriptive summaries will include mean, standard error, median, minimum, and maximum. Other concurrently measured hemodynamic parameters (i.e., RA, PAs, PAd, cuff SBP, cuff DBP, calculated MAP, and HR) will also be summarized.

The results of the foregoing study establish that conivaptan has a surprisingly favorable hemodynamic effect as an add-on therapy to normal treatment with ACE inhibitors. Eighty-five percent of the patients in this study were treated with ACE inhibitors (plus conivaptan). As shown in Figure 1, conivaptan caused significant reductions in PCWP. Figure 2 shows that conivaptan caused a significant reduction in RAP.

The compositions to be employed in the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms for treating and preventing heart failure and ventricular dilation. The compounds can be administered by injection, that is, intra-venously, intramuscularly, intracutaneously, subcutaneously, submucosally, intraductally, intraduodenally, or intraperitoneally. Also, the compounds can be administered by inhalation, for example, intranasally. Additionally, the compositions can be administered transdermally. It will be obvious to those skilled in the art that the following

-24-

dosage forms may comprise as the active component, either a compound as a free base, acid, or a corresponding pharmaceutically acceptable salt of such compound. The active compound generally is present in a concentration of about 5% to about 95% by weight of the formulation.

5 For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, 10 lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

15 In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

20 The powders and tablets preferably contain from 5% or 10% to about 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation 25 of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

30 For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection,

-25-

liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

5        Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

10      Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, 15      solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as 20      packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

25      The quantity of each active component in a unit-dose preparation may be varied or adjusted from 1 to 1000 mg, preferably 10 to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

The following examples illustrate typical formulations that can be utilized in the invention.

-26-

Tablet Formulation

Ingredient	Amount (mg)
Conivaptan	25
Quinapril hydrochloride	20
Lactose	30
Cornstarch (for mix)	10
Cornstarch (paste)	10
Magnesium stearate (1%)	5
Total	100

5

The conivaptan, ACE inhibitor, lactose, and cornstarch (for mix) are blended to uniformity. The cornstarch (for paste) is suspended in 200 mL of water and heated with stirring to form a paste. The paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are lubricated with the 1% magnesium stearate and pressed into a tablet. Such tablets can be administered to a human from one to four times a day for treatment of CHF.

Preparation for Oral Solution

Ingredient	Amount
YM-471	400 mg
Quinapril	20 mg
Sorbitol solution (70% N.F.)	40 mL
Sodium benzoate	20 mg
Saccharin	5 mg
Red dye	10 mg
Cherry flavor	20 mg
Distilled water q.s.	100 mL

10

The sorbitol solution is added to 40 mL of distilled water, and the vasopressin antagonist and ACE inhibitor are dissolved therein. The saccharin,

-27-

sodium benzoate, flavor, and dye are added and dissolved. The volume is adjusted to 100 mL with distilled water. Each milliliter of syrup contains 4 mg of invention composition.

PARENTERAL SOLUTION


- 5        In a solution of 700 mL of propylene glycol and 200 mL of water for injection is suspended 20 g of vasopressin antagonist OPC-31260 and 5 g of enalaprilat. After suspension is complete, the pH is adjusted to 6.5 with 1N sodium hydroxide, and the volume is made up to 1000 mL with water for injection. The formulation is sterilized, filled into 5.0 mL ampoules each  
10      containing 2.0 mL, and sealed under nitrogen.

-28-

## CLAIMS

What is claimed is:

1. A pharmaceutical composition comprising an effective amount of an angiotensin-converting enzyme inhibitor and an effective amount of a vasopressin antagonist.
- 5
2. A composition according to Claim 1 employing an ACE inhibitor selected from captopril, enalapril, enalaprilat, lisinopril, ramipril, zofenopril, trandolapril, temocapril, ceranapril, alacepril, delapril, pentopril, quinapril, quinaprilat, moexipril, rentiaprile, duinapril, spirapril, cilazapril, perindopril, and fosinopril.
- 10
3. A composition according to Claim 1 employing a vasopressin antagonist of Formula I



wherein R and R<sup>5</sup> are hydrogen or lower alkyl;

15 R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> independently are hydrogen, halo, lower alkyl, lower alkoxy, amino, alkylamino, or dialkylamino; and

R<sup>4</sup> is hydrogen, phenyl or substituted phenyl, and pharmaceutically acceptable salts thereof.

-29-

4. A composition according to Claim 3 in which the vasopressin antagonist is conivaptan.
5. A composition according to Claim 2 comprising an ACE inhibitor selected from quinapril hydrochloride, ramipril, enalapril, or moexipril.
- 5 6. A composition according to Claim 5 comprising a vasopressin antagonist selected from conivaptan or a salt thereof.
7. A composition comprising conivaptan and quinapril.
8. A method for treating ventricular dilation, and/or heart failure in a mammal comprising administering an effective amount of a combination of at least one angiotensin-converting enzyme inhibitor and at least one vasopressin antagonist.  
10

**THIS PAGE BLANK (USPTO)**

1/2




FIG. 1 Change from Baseline in PCWP

**THIS PAGE BLANK (USPTO)**

**WO 01/54677**

**PCT/US00/32569**

**2/2**

**MISSING AT THE TIME OF PUBLICATION**

**THIS PAGE BLANK (USPTO)**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number  
**WO 01/54677 A3**

(51) International Patent Classification<sup>2</sup>: **A61K 45/06**, (74) Agents: **FEDERMAN, Evan, J.; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 et al. (US).**  
31/55, 38/55, A61P 9/00

(21) International Application Number: **PCT/US00/32569**

(22) International Filing Date:  
30 November 2000 (30.11.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:  
60/178,169 26 January 2000 (26.01.2000) US

(71) Applicant (for all designated States except US):  
**WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).**

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PRESSLER, Millton, Lethan [US/US]; 7194 Partridge Way, Saline, MI 48176 (US).**

(81) Designated States (national): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
31 January 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/54677 A3

(54) Title: ACE INHIBITOR-VASOPRESSIN ANTAGONIST COMBINATIONS

(57) Abstract: Combinations of ACE inhibitors and vasopressin antagonists are useful to slow and reverse the process of ventricular dilation, and CHF in mammals.

**THIS PAGE BLANK (USPTO)**

## INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 00/32569

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 A61K45/06 A61K31/55 A61K38/55 A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 205 334 A (E.R.SQUIBB & SONS) 17 December 1986 (1986-12-17) claim 1 page 4, line 9-13 page 4, line 33 -page 5, line 4 ---	1,2,8
X	EP 0 344 995 A (E.R.SQUIBB & SONS) 6 December 1989 (1989-12-06) claims 1,6,11 ---	1,2
X	EP 0 365 134 A (SMITHKLINE BEECHAM) 25 April 1990 (1990-04-25) claim 1 page 5, line 5-15 ---	1,2,8 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

- \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the International search

1 October 2001

Date of mailing of the International search report

09/10/2001

Name and mailing address of the ISA  
 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel: (+31-70) 340-2040, fax: 31 651 epo nl.  
 Fax: (+31-70) 340-3016

Authorized officer

Peeters, J

## INTERNATIONAL SEARCH REPORT

National Application No  
PCT/US 00/32569

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 229 329 A (E.R.SQUIBB & SONS) 22 July 1987 (1987-07-22) claim 1 page 4, line 14-22 page 5, line 4-11 -----	1,2,8

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No  
PCT/US 00/32569

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 205334	A	17-12-1986	AU	592344 B2	11-01-1990
			AU	5837886 A	18-12-1986
			CA	1271747 A1	17-07-1990
			DK	272686 A	13-12-1986
			EP	0205334 A2	17-12-1986
			HU	47084 A2	30-01-1989
			JP	1959057 C	10-08-1995
			JP	6086434 B	02-11-1994
			JP	61286367 A	16-12-1986
			NZ	216416 A	06-01-1989
			US	4748239 A	31-05-1988
			ZA	8604161 A	25-02-1987
EP 344995	A	06-12-1989	AU	607612 B2	07-03-1991
			AU	3493089 A	07-12-1989
			DK	265789 A	02-12-1989
			EP	0344995 A2	06-12-1989
			HU	58521 A2	30-03-1992
			JP	2025422 A	26-01-1990
			US	5037821 A	06-08-1991
			ZA	8903735 A	28-02-1990
EP 365134	A	25-04-1990	EP	0365134 A1	25-04-1990
			JP	2121925 A	09-05-1990
EP 229329	A	22-07-1987	AT	92047 T	15-08-1993
			AU	591726 B2	14-12-1989
			AU	6530386 A	18-06-1987
			CA	1271748 A1	17-07-1990
			CA	1294617 A2	21-01-1992
			CN	86108530 A ,B	17-06-1987
			CZ	8609154 A3	19-01-1994
			DD	258807 A5	03-08-1988
			DD	270071 A5	19-07-1989
			DE	3688788 A1	02-09-1993
			DE	3688788 T2	03-03-1994
			DK	595686 A ,B,	13-06-1987
			EP	0229329 A1	22-07-1987
			ES	2058059 T3	01-11-1994
			FI	865056 A ,B,	13-06-1987
			HU	43572 A2	30-11-1987
			HU	199806 B	28-03-1990
			IE	61757 B	30-11-1994
			IL	95607 A	25-05-1992
			JP	6086435 B	02-11-1994
			JP	62164668 A	21-07-1987
			KR	9001177 B1	27-02-1990
			NO	865012 A ,B,	15-06-1987
			NZ	218292 A	28-10-1988
			PH	25223 A	27-03-1991
			PL	271723 A1	08-12-1988
			PT	83917 A ,B	01-01-1987
			SU	1790575 A3	23-01-1993
			ZA	8608598 A	24-06-1987
			SU	1542414 A3	07-02-1990
			US	4752645 A	21-06-1988

**THIS PAGE BLANK (USPTO)**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number  
**WO 01/054677 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 45/06, 31/55, 38/55, A61P 9/00**
- (21) International Application Number: **PCT/US00/32569**
- (22) International Filing Date:  
30 November 2000 (30.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/178,169 26 January 2000 (26.01.2000) US
- (71) Applicant (for all designated States except US):  
WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): PRESSLER, Millton, Lethan [US/US]; 7194 Partridge Way, Saline, MI 48176 (US).
- (74) Agents: FEDERMAN, Evan, J.; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 et al. (US).
- (81) Designated States (national): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
31 January 2002
- (48) Date of publication of this corrected version:  
12 June 2003
- (15) Information about Correction:  
see PCT Gazette No. 24/2003 of 12 June 2003, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/054677 A3

(54) Title: ACE INHIBITOR-VASOPRESSIN ANTAGONIST COMBINATIONS

(57) Abstract: Combinations of ACE inhibitors and vasopressin antagonists are useful to slow and reverse the process of ventricular dilation, and CHF in mammals.

**THIS PAGE BLANK (USPTO)**

-1-

## ACE INHIBITOR-VASOPRESSIN ANTAGONIST COMBINATIONS

### FIELD OF THE INVENTION

This invention relates to compositions comprising a compound which inhibits the actions of angiotensin-converting enzyme and a compound which 5 inhibits the actions of vasopressin enzymes, and the use of such compositions for treating ventricular dilation, heart failure, and cardiovascular pathologies.

### BACKGROUND OF THE INVENTION

Heart failure is a pathophysiologic state in which the heart is unable to pump sufficient blood to meet the metabolic needs of the body. It may be caused 10 by a number of factors affecting the myocardium, some altering systolic function and others interfering with diastolic function and/or both. Ischemic heart disease is the most common cause of heart failure in Western countries. Other common etiologies include: (1) hypertension and hypertrophic cardiomyopathy; (2) dilated cardiomyopathy of known cause (e.g., secondary to diabetes; hypo- or 15 hyperthyroidism; viral or parasitic infection); (3) idiopathic dilated cardiomyopathy; and (4) congenital or acquired valvular disease. Severity of chronic heart failure (CHF) is often categorized by the New York Heart Association (NYHA) Functional Classification system.

Development and progression of CHF is a major unsolved problem. Heart 20 failure is one of the few cardiovascular diseases with increasing prevalence, now afflicting 3 to 4 million persons in the United States of America (USA), a like number in Europe, and 200,000 in Canada. It accounts for tens of billions of dollars of health care expenditure in the USA alone. It is more common with advancing age: 75% of hospitalized CHF patients are over 65 and 50% are over 25 75 years of age. CHF admissions comprise the No. 1 diagnosis-related group (DRG) for the Medicare population; 800,000 to 900,000 hospitalizations in the USA per year are related to CHF decompensation. The prognosis remains poor despite increasing understanding of mechanisms and new treatments. Around

-2-

465,000 new cases of heart failure develop in the USA annually and there are over 250,000 deaths. Fifty percent to 60% of patients are dead within 5 years of diagnosis; 1-year mortality is approximately 40% to 50% for those with severe functional impairment. Roughly 20% of the heart failure population (600,000 persons in the USA) suffers from severe (NYHA Functional Class III/IV) CHF.

Chronic treatments for CHF include digoxin, diuretics, angiotensin converting enzyme (ACE) inhibitors, the combination of hydralazine and isosorbide dinitrate, and  $\beta$ -blockers, specifically carvedilol. Acute medical therapies for heart failure also include inotropic agents (e.g., dobutamine, milrinone, amrinone), parenteral loop diuretics, and oxygen. Several landmark studies in the 1980s and early 1990s (e.g., CONSENSUS; SOLVD) showed that ACE inhibitors could lengthen survival and reduce the number of hospitalizations of patients with symptomatic CHF (*N. Eng. J. Med.*, 1987;316:1429-1435; and 1991;325:293-302). Even patients with asymptomatic left ventricular (LV) systolic dysfunction were found to benefit by treatment with an ACE inhibitor (SOLVD prevention study). The postulated mechanism is that ACE inhibitors prevent or reduce the upregulation of the renin-angiotensin system (RAS). Unfortunately, no currently available ACE inhibitor is completely effective in halting the progression of heart failure. The majority of CHF patients given optimal treatment with an ACE inhibitor still progress to intractable pump failure or suffer sudden death. As a result, therapies have been directed at other factors associated with progression of heart failure. Increased sympathetic tone and plasma catecholamines are believed to play a role. The degree of functional impairment is roughly correlated with magnitude of sympathetic upregulation. Several  $\beta$ -blockers have been investigated albeit with mixed results. Carvedilol, a nonselective  $\beta$ -blocker, has been shown to lessen combined CHF morbidity and mortality in chronic mild to moderate heart failure. However, some patients decompensate during initiation of drug therapy, and its use is not approved in patients with acute heart failure. Furthermore, patients treated with carvedilol plus an ACE inhibitor continue to progress inexorably toward death. Patients with

-3-

advanced heart failure have limited medical options even though ACE inhibitors and carvedilol are useful adjuncts.

Heart failure may be precipitated acutely by the loss of viable myocardium, but its gradual progression over many years involves many interdependent factors: catecholamines and other hormonal factors (e.g., 5 angiotensin II [Ang II]; aldosterone; arginine vasopressin [AVP]; Endothelin-1 [ET-1]; Atrial Natriuretic Factor [ANF]) are thought to contribute to the pathophysiology of LV enlargement and myocardial "remodeling" (Pauleur, *Am. J. Cardiol.*, 1994;73:36C-39C). The benefits of ACE inhibition have pointed to the key role of the renin-angiotensin system (especially Ang II) in LV dilation and heart failure development. However, the progression of heart failure may not involve the same underlying mechanism throughout its course. One set of factors 10 may play a primary role in the onset and early progression of ventricular dysfunction, other substances in the middle phase of symptoms and events, and different factors in the terminal phases of the disease. Furthermore, the benefits 15 and risks of therapeutic interventions may vary with the severity of heart failure. Patients with severe heart failure are most prone to hospitalization and most restricted in their functional capacity. These are the patients that become unresponsive to ACE inhibitors. Of note, serum sodium concentration is an independent prognostic factor for outcome of patients with severe CHF. 20 Hyponatremic patients have a much higher mortality and frequently have serial admissions for heart failure decompensation. These observations suggest that AVP, the neurohormone responsible for regulation of serum osmolality, may be a key factor in progression of heart failure in severely compromised patients. 25 AVP, a neuropeptide hormone, is synthesized in the hypothalamus, stored in the posterior pituitary, and released into the circulation after activation of neurosecretory cells. There are 2 AVP receptor subtypes. The V<sub>1A</sub>-subtype mediates contraction in blood vessels and platelet aggregation. V<sub>1</sub> receptors are also involved in the stimulating effect of AVP on adrenocorticotropic hormone 30 (ACTH) secretion. The V<sub>2</sub> receptor is coupled to aquaporine channels in the human kidney and modulates water clearance.

-4-

I have now discovered that compounds which inhibit ACE can be used in conjunction with compounds which inhibit vasopressin enzymes to achieve surprisingly good results in treating CHF and related cardiovascular diseases like ventricular dilation, cardiac inefficiency, and hypertension.

5

#### SUMMARY OF THE INVENTION

10


This invention provides a composition comprised of an ACE inhibitor and a vasopressin antagonist. Any ACE inhibitor can be employed in this invention. In a preferred embodiment, the ACE inhibitor is selected from captopril, enalapril, enalaprilat, lisinopril, ramipril, zofenopril, ceroanapril, alacepril, benazepril, delapril, pentopril, quinapril, quinaprilat, moexipril, rentiaprile, quinapril, spirapril, cilazapril, perindopril, and fosinopril.

15

The vasopressin antagonist to be employed is any chemical compound that is effective in inhibiting the biological activity of any arginine vasopressin or antidiuretic hormone. Numerous compounds are known to be vasopressin antagonists, and any of such compounds can be utilized in the composition of this invention.

20

In a preferred embodiment, the vasopressin antagonist to be utilized is a condensed benzazepine such as those described in U.S. Patent No. 5,723,606, incorporated herein by reference. In a further preferred embodiment, the vasopressin antagonist is an imidazo benzazepine of the Formula I



wherein R and R<sup>5</sup> are hydrogen or lower alkyl;


-5-

$R^1$ ,  $R^2$ , and  $R^3$  independently are hydrogen, halo, lower alkyl, lower alkoxy, amino, alkylamino, or dialkylamino; and

$R^4$  is hydrogen, phenyl or substituted phenyl, and pharmaceutically acceptable salts thereof.

5 An especially preferred vasopressin antagonist to be used in accordance with this invention is Conivaptan, which is N-[4-(2-methyl-4,5,6-tetrahydromidazo[4,5-*d*][1]benzazepin-6-ylcarbonyl)phenyl]biphenyl-2-carboxamide hydrochloride. Conivaptan is also referred to as CI-1025, as well as YM087, and has the structural formula below

10



Other vasopressin antagonists that can be employed accordingly to this invention include the benzoheterocyclic compounds described in U.S. Patents No. 5,258,510, incorporated herein by reference. Preferred compounds from this class to be used herein include the following:

15

5-Dimethylamino-1-[4-(2-methylbenzoylamino)-benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine;

5-Dimethylamino-1-[2-chloro-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine;

5-Methylamino-1-[2-chloro-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine;

20

5-Cyclopropylamino-1-[2-chloro-4-(2-methylbenzoylamino)benzoxyl]-2,3,4,5-tetrahydro-1H-benzazepine;

5-Cyclopropylamino-1-[2-chloro-4-(2-chlorobenzoylamino)benzoxyl]-2,3,4,5-tetrahydro-1H-benzazepine;

-6-

5-Dimethylamino-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-  
2,3,4,5-tetrahydro-1H-benzazepine;  
5-Dimethylamino-1-[2-methoxy-4-(2-methylbenzoylamino)benzoyl]-  
1,2,3,4-tetrahydroquinoline;  
5-Chloro-5-methylamino-1-[4-(2-methylbenzoylamino)benzoxyl]-2,3,4,5-  
tetrahydro-1H-benzazepine; and  
7-Chloro-5-methylamino-1-[4-(2-chlorobenzoylamino)benzoxyl]-2,3,4,5-  
tetrahydro-1H-benzazepine.

Other vasopressin antagonists that can be employed according to this  
10 invention include those described in U.S. Patent Nos. 5,225,402; 5,258,510;  
5,338,755; 5,719,155; and 5,710,150, all of which are incorporated herein by  
reference. Specific vasopressin antagonists include YM471, OPC-31260,  
OPC-21268, OPC-41061, SR-121463, SR-49059, VPA-985, CL-385004,  
FR-161282, JVT-605, VP-339, WAY-140288, and the like.

15 The invention also provides a method for treating CHF, ventricular  
dilation, and hypertension by administering to a mammal in need of treatment an  
effective amount of the combination of an ACE inhibitor and a vasopressin  
antagonist.

#### BRIEF DESCRIPTION OF FIGURES

20 Figure 1 shows the reduction in baseline pulmonary capillary wedge  
pressure (PCWP) caused by various doses of conivaptan in patients receiving an  
ACE inhibitor.

Figure 2 shows the reduction in right atrial pressure (RAP) caused by  
various doses of conivaptan in patients receiving an ACE inhibitor.

25

#### DETAILED DESCRIPTION OF THE INVENTION

The ACE inhibitors to be employed in the compositions of this invention  
are well-known in the art, and several are used routinely for treating hypertension.

-7-

For example, captopril and its analogs are described in U.S. Patent Nos. 5,238,924 and 4,258,027. Enalapril, enalaprilat, and closely related analogs are described in U.S. Patent Nos. 4,374,829; 4,472,380; and 4,264,611. Moexipril, quinapril, quinaprilat, and related analogs are described in U.S. Patent Nos. 4,743,450 and 4,344,949. Ramipril and its analogs are described in U.S. Patent Nos. 4,587,258 and 5,061,722. All of the foregoing patents are incorporated herein by reference for their teaching of typical ACE inhibitors which can be utilized in combination with a vasopressin antagonist according to this invention. Other ACE inhibitors which can be utilized include fosinopril, fasidotril, glycopril, idrapril, imidapril, mixanpril, perindopril, spirapril, spiraprilat, temocapril, trandolapril, zofenopril, zofenoprilat, utilapril, sampatrilat, SA 7060, DU 1777, BMS 186716, and C 112. All of the references cited herein are incorporated by reference for their teaching of components of the now claimed combinations.

The compositions of this invention will contain an ACE inhibitor and a vasopressin antagonist in a weight ratio of about 0.05:1 to about 1000:1, and typically about 1:1 to about 500:1, and ideally about 1:1 to about 5:1. A typical composition, for example, will have 20 mg of quinapril hydrochloride and about 10 mg of conivaptan. All that is required is that amounts of each component are used which are effective to inhibit or reverse CHF, ventricular dilation, or hypertension. The compounds can be administered separately to a patient to effect treatment according to this invention.

As used herein, "patient" means a mammal suffering from a cardiovascular disorder such as CHF and in need of treatment. Patients include humans and animals such as dogs, cats, and sheep. The method of this invention is practiced by administering an effective amount of an ACE inhibitor and a vasopressin antagonist to a patient.

An "effective amount" as used herein is the individual quantities of ACE inhibitor and vasopressin antagonist that are routinely used in clinical treatment of hypertension and other cardiovascular disorders. Typical effective amounts will be about 5 to about 500 mg/kg of ACE inhibitor, and about 1 to about 100 mg/kg of vasopressin antagonist. The "effective amount" is that quantity that gives a positive effect in treating the CHF, for example, by causing a reduction in PCWP or in RAP. The precise dosage that is effective according to this invention will be

-8-

determined by the attending medical practitioner, taking into account the specific ACE inhibitor and vasopressin antagonist being administered, the particular condition of the patient being treated, the duration of the treatment and severity of the disease, and such other factors routinely considered when practicing sound medical judgment.

The combination of an ACE inhibitor with a vasopressin antagonist is synergistic in its ability to treat cardiovascular pathologies such as CHF, as well as hypertension, and left ventricular systolic dysfunction.

Terms used in this specification have the following meanings:

10	CHF	Congestive Heart Failure
	NYHA	New York Heart Association
	CI	Cardiac Index
	PCWP	Pulmonary Capillary Wedge Pressure
	SBP	Systolic Blood Pressure
15	PVR	Pulmonary Vascular Resistance
	SVR	Systemic Vascular Resistance
	RA	Right Atrial Pressure
	PAs	Pulmonary Artery Systolic Pressure
	PAd	Pulmonary Artery Diastolic Pressure
20	DBP	Diastolic Blood Pressure
	MAP	Mean Arterial Pressure
	LV	Left Ventricular
	CAD	Coronary Artery Disease
	ALT	Alanine Aminotransferase
25	AST	Aspartate Aminotransferase
	Alk Phos	Alkaline Phosphatase
	LV-EF	Left Ventricular Ejection Fraction
	MuGA	Multi-Gated Radionuclide Ventriculogram
	ACE	Angiotensin Converting Enzyme
30	Cr	Serum Creatinine
	BUN	Blood Urea Nitrogen
	WBC	White Blood Cells
	Hgb	Hemoglobin

-9-

	ULN	Upper Limit of Normal
	HR	Heart Rate
	CRF	Case Report Form
	COPD	Chronic Obstructive Pulmonary Disease
5	FVC	Forced Vital Capacity
	FEV <sub>1</sub>	Forced Expiratory Volume in 1 Second

#### EXAMPLE 1

The following studies establish the clinical efficacy of YM087 and combinations of ACE inhibitors and vasopressin antagonists.

10 Preclinical pharmacologic studies have demonstrated potent binding of YM087 conivaptan to AVP receptors and antagonism of the vascular and renal effects of AVP. YM087 has high affinity for V<sub>1A</sub>- and V<sub>2</sub>-receptors with pKi (negative log of the binding inhibition constant) of 8.20 for human V<sub>1A</sub>-receptors and 8.95 for human V<sub>2</sub>-receptors expressed in COS-1 cells.

15 **Clinical Pharmacology**

YM087 given orally to rats antagonizes the AVP-induced pressor response (V<sub>1A</sub> antagonism) in a dose-related manner, with the dose that reduced the AVP response by 50% (ID<sub>50</sub>) being 0.32 mg/kg; ID<sub>50</sub> for a similar experiment using intravenous (IV) YM087 in dogs was 0.026 mg/kg. In conscious dogs, oral YM087 (0.03 to 0.3 mg/kg) increased urinary output (V<sub>2</sub> antagonism) and reduced urinary osmolality (from 1500 to <100 mOsm/kg H<sub>2</sub>O) in a dose-related manner. Unlike furosemide, YM087 has little or no effect on urinary sodium (Na) or potassium (K) excretion. In dogs with heart failure induced by rapid right ventricular pacing, intravenous administration of YM087 (0.1 mg/kg) significantly improved the depressed cardiac function and produced a water diuresis.

Oral absorption of YM087 is rapid (peak concentrations reached between 0.5 to 1 hour in the rat and dog, respectively) and occurs predominantly in the small intestine. There is a marked food effect with absorption reduced by >50% in dogs after a meal. The elimination half-life is 1 hour in rats and 2 hours in dogs. Mass balance studies show the majority of radioactive tracer excreted in the feces.

-10-

The preclinical toxicologic potential of YM087 has been extensively evaluated, and all findings were evaluated for relevance to human risk assessment and impact on clinical trial design. Findings of potential concern were bone marrow changes in dogs and effects on fertility in rats.

5            Histopathologic changes in bone marrow were observed in both 2- and 13-week oral studies in dogs with systemic exposures 28- to 87-fold higher than the maximum anticipated human exposure. Decreased peripheral erythrocyte, leukocyte, and/or platelet counts occurred in affected dogs in the 13-week study. Bone marrow and peripheral blood changes were reversible.

10          YM087 did not affect reproductive performance of male rats. In the 13-week, repeated oral dose study in rats, more females at 10 mg/kg were in diestrus or proestrus and fewer were in estrus than in controls, and uterine weights were decreased at all doses; associated systemic exposures were 0.06- to 3.2-fold the maximum anticipated human exposure. In the female fertility study in rats, 15 reduced fertility index, increased implantation loss, and decreased live fetuses were observed in females given 100 mg/kg orally for 2 weeks prior to mating with untreated males. Effects on estrous cycle and fertility in female rats may be related to alterations in serum hormone levels resulting from pharmacologic activity of YM087. YM087 was not teratogenic in rats or rabbits.

20          Other drug-related effects, including diuresis and hepatocellular hypertrophy, were of less concern due to the nature of the effects or the high exposures at which the effects occurred compared to exposures anticipated in clinical trials.

25          YM087 was not mutagenic in bacteria, and was not clastogenic in human lymphocytes in vitro or in bone marrow of rats. No toxicity was observed in 4-week, IV studies with the glycerin formulation at maximum achievable doses, 2.5 mg/kg in rats and 2 mg/kg in dogs.

30          In summary, toxicological findings of potential concern for human risk assessment were reversible effects on bone marrow in dogs and reversible effects on estrus cycle and decreased fertility in rats. Findings in bone marrow were observed at exposures in excess of 23 times exposure expected in humans given the maximum dose of 120 mg once daily (QD), while effects on estrus cycle occurred at exposures from 0.05- to 3-fold the expected human exposure at

-11-

120 mg QD. Other drug-related findings in toxicology studies were considered secondary to pharmacologic activity or a functional adaptation to exposure to YM087.

5 YM087 has been given to approximately 250 healthy subjects who participated in a total of 15 Phase 1 studies (8 in Japan and 7 in Europe). Subjects taking oral medication received either a single dose of YM087 (dose range 0.2 through 120 mg) QD or 30 or 120 mg YM087 administered as a divided dose twice daily (BID). Subjects received YM087 as a single IV injection once daily over a dose range of 0.2 to 250 µg/kg or up to a maximum of 50 mg.

10 Inhibition of AVP-induced platelet aggregation (evidence of V<sub>1A</sub> antagonist activity) was seen among subjects who received YM087 at 20 mg/day orally or 2.5 mg IV. Total inhibition of AVP-induced dermal vasoconstriction was observed among subjects who received YM087 50 mg IV.

15 Normal subjects have demonstrated aquaretic action (evidence of V<sub>2</sub>-receptor antagonism) accompanied by a decrease in urine osmolarity starting at 15 mg oral or 50 µg/kg IV. At higher doses aquaretic effects were more pronounced and at 120 mg QD or 60 mg BID given orally or 50 mg given IV were considered too uncomfortable in normal subjects to be tolerable. YM087 at IV doses up to 250 µg/kg and 50 mg/day increased urine production rate for up to 20 3 and 6 hours postdosing, respectively.

25 Under fasting conditions, YM087 is rapidly absorbed, time to maximum plasma concentration (t<sub>max</sub>) being reached at around 1 hour. The mean oral bioavailability of a 60-mg dose is 44% under fasting conditions; bioavailability is decreased after intake with food. A high-fat breakfast reduced bioavailability of single 15- to 90-mg doses of YM087 to 43% to 59% of the fasted value, and peak plasma levels were reduced to 24% to 54% of the fasting value. Oral YM087 demonstrated a nonlinear pharmacokinetic profile. Repeated BID oral doses of YM087, 60 mg, result in unexpectedly high plasma levels after the second dose, possibly caused by reduced first-pass metabolism. YM087 displays 30 2 compartment pharmacokinetics, with an elimination half-life of 4 to 5 hours. Elderly subjects have a similar elimination half-life as healthy, young volunteers.

-12-

The pharmacokinetics of orally administered YM087 (20 mg) were not affected when combined with either 0.5 mg IV digoxin or 25 mg oral captopril (each given as a single dose).

#### Safety

5 Among approximately 250 subjects treated, no major safety concerns were identified. One patient with severe CHF who received YM087 80 mg/day for 4 days experienced a generalized tonic clonic seizure, which the investigator could not exclude as related to study drug. The most frequent adverse events regardless of treatment association were mild or moderate thirst and mild headache. Other 10 adverse events included flushes, a sensation of cold extremities, abdominal complaints, abnormal stools, syncope, dizziness, palpitations, and postural hypotension. Three subjects who received YM087 and one subject who received placebo developed minor, reversible leukopenia. No drug-related trend was observed in biochemical or hematological laboratory parameters. At higher doses, 15 urinary osmolarity decreased and plasma osmolarity increased with or without an increase in plasma sodium. These observations were considered related to antagonism of V<sub>2</sub> receptors and not a safety concern. Vital signs (blood pressure and heart rate) were unaffected by YM087.

#### EXAMPLE 2

##### ACE + Vasopressin Antagonists in CHF

20 This trial is a double-blind, placebo-controlled study of the intravenous dose response of YM087 on cardiopulmonary hemodynamics in 142 patients with Class III/IV heart failure. These patients have advanced CHF/LV dysfunction. Patients must be receiving background therapy of diuretics, ACE inhibitors, and 25 optionally digoxin and/or β-blocker; patients will be stratified as to whether they are receiving concomitant β-blocker treatment. Eighty-five percent of the patients in this study received an ACE inhibitor and YM087. Patients should take their daily dose of concomitant heart failure medications within 2 hours of catheter insertion. No additional doses of background heart failure medications should be 30 administered during the study treatment phase. After insertion of a balloon-floatation pulmonary artery catheter, serial measurements will be obtained over an

-13-


8- to 18-hour baseline and stabilization period. Patients meeting baseline eligibility criteria ( $CI \leq 2.6 \text{ L/min/m}^2$ ;  $PCWP \geq 16 \text{ mmHg}$ ) after catheter stability is assured will be administered an IV dose (30-minute infusion) of YM087 or placebo and monitored for the subsequent 12 hours. The mean baseline PCWP in this study group was 24.2 mmHg. The mean baseline CI was 2.1  $\text{L/min/m}^2$ .

5 Hemodynamic parameters and vital signs will be measured at baseline during the 2 hours prior to drug administration and 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours after start of the IV infusion. A urethral cathether will be placed and urine output will be measured hourly for 2 hours prior until 12 hours poststudy drug

10 administration. Fluid intake will be restricted to 250 mL every 2 hours (except at time of IV infusion) from time of insertion of Swan-Ganz catheter and throughout the treatment period. YM087 plasma levels will be determined at 1, 3, and 8 hours posttreatment. Serum electrolytes, BUN, creatinine, and serum osmolality will be measured at baseline and 4 and 12 hours posttreatment. Clinical laboratory and

15 vasopressin plasma levels will be measured at baseline and 12 hours postdrug administration. A numeric rating scale for assessing dyspnea will be administered at baseline and 12 hours after study drug administration. The dosing and analysis schedule used in this study is shown in Table 1.

TABLE 1



-14-

**Screening and Baseline Phase (10-20 Hours)**

This phase allows the investigator to evaluate patients who may qualify for entry into the treatment period and to assess baseline values for a number of study parameters. An informed consent must be signed. A medical history, physical examination, and assessment of NYHA functional class will be done. Clinical laboratory parameters will be measured. If left ventricular ejection fraction (LV-EF) has not been measured during the previous 3 months, the patient will undergo radionuclide, contrast ventriculography, or 2-dimensional echocardiography to measure LV-EF.

Patients must remain on stable doses of background heart failure medications throughout the baseline and treatment phase. Patients should take a dose of their concomitant heart failure medications within 2 hours of Swan-Ganz catheter insertion. No additional dose of background medications should be administered during the study treatment phase. After insertion of a balloon-floatation pulmonary artery catheter, several measurements of hemodynamic parameters will be obtained over a 8- to 18-hour baseline and stabilization period. Patients meeting baseline eligibility criteria ( $CI \leq 2.6 \text{ L/min/m}^2$ ; PCWP  $\geq 16 \text{ mmHg}$ ) on successive readings at least 30 minutes apart during 2 hours prior to study drug administration will enter the treatment phase. Additional measurements of hemodynamic parameters over a larger baseline period ( $\geq 2 \text{ hours}$ ) may be required to meet the reproducibility criteria. The 2 successive measurements of PCWP and CO must be  $\pm 10\%$  and  $\pm 15\%$ , respectively, of the mean. Patients should fast 6 hours prior to baseline measurements and must remain fasting for the first 6 hours of the 12-hour treatment phase.

Patients who qualify for entry will have blood drawn for a baseline assessment of clinical laboratory and vasopressin plasma levels. A urethral cathether should be placed and urinary output measurements will be obtained hourly for  $\geq 2$  hours prior to study drug administration and thereafter during the treatment phase. Hemodynamic measurements should be obtained at least 30 minutes after insertion of the urethral catheter. Fluid intake will be restricted to 250 mL every 2 hours (except at time of IV infusion) from time of insertion of Swan-Ganz catheter and throughout treatment period. Vital signs will be assessed

-15-

at least every 4 hours. A numeric rating scale for assessing dyspnea will be administered within 1 hour of study drug administration.

**Treatment Phase (12 Hours):**

Patients meeting baseline eligibility criteria will be randomized within an hour to receive double-blind IV bolus dose, administered over 30 minutes, of placebo or 1 of 3 doses of YM087 (10, 20, or 40 mg) in a 1:1:1:1 ratio. Patients should refrain from taking concomitant heart failure medications during the 12-hour treatment period. Patients will be stratified as to whether they are receiving concomitant treatment with a  $\beta$ -blocker. Hemodynamic parameters (cardiac output, intrapulmonary and systemic pressures) and vital signs will be measured at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after start of the IV infusion. Clinical laboratory and vasopressin plasma levels will be measured 12 hours postdose. YM087 plasma levels will be determined at 1, 3, and 8 hours posttreatment. Serum electrolytes, BUN, creatinine, serum osmolality will be measured at 4 and 12 hours posttreatment. Hourly urine output measurements will be obtained during the entire 12-hour treatment phase. The numeric rating scale for assessing dyspnea will be administered 12 hours postadministration of study medication.

**Posttreatment Phase (24-48 Hours) After Administration of Study Medication:**

Patients must return for an outpatient follow-up visit at least 24 to 48 hours after administration of study medication. Patients will be followed for clinical assessment of adverse events. Clinical laboratory parameters will be measured. Background heart failure medications will be readjusted if necessary for safety/tolerance of the patient.

**25 STUDY POPULATION**

All patients enrolled into this study will have NYHA Class III/IV heart failure due to systolic LV dysfunction.

-16-

#### **Source and Number of Patients**

A total of 142 patients (35 per treatment group) will be enrolled at 20 study centers. Each site is expected to enroll 6 to 8 patients. Enrollment is competitive and will stop when the study is complete.

#### **5 Patient-Selection Criteria**

##### Inclusion Criteria

Patients acceptable for inclusion into the study must meet the following criteria:

- Males or females 18 to 80 years of age; females must be postmenopausal, surgically sterilized, or practicing a suitable method of birth control so that in the opinion of the investigator, they will not become pregnant during the study;
- Symptomatic heart failure with Class III/IV functional impairment by NYHA criteria;
- Current therapy for heart failure consisting of at least 1 month duration of an ACE inhibitor, loop diuretic, and optionally digoxin and/or  $\beta$ -blocker;
- Cardiac index  $\leq 2.6$  L/min/m<sup>2</sup>; and PCWP  $\geq 16$  mmHg on successive readings at least 30 minutes apart prior to study drug administration; and
- Signed informed consent.

#### **20 Exclusion Criteria**

Presence of any of the following conditions will exclude the patient from being eligible for study:

- Breast feeding or pregnant;
- Patients with supine systolic blood pressure  $< 95$  mmHg or uncontrolled hypertension;
- Patients with more than 2+ edema (above the knee);
- Uncontrolled symptomatic brady- or tachyarrhythmias (e.g., sinus arrest; second-degree Mobitz type II) or third-degree AV block; atrial fibrillation or flutter; frequent runs of ventricular tachycardia); patients with dual chamber

-17-

- pacemakers and/or implantable defibrillators are eligible, if the device has been implanted >60 days prior to screening;
- Unstable angina pectoris and/or acute myocardial infarction within 1 month of baseline;
  - 5     • Patients with severe COPD (FVC ≤1.5 L; FEV<sub>1</sub> ≤1.0 L) or primary pulmonary hypertension;
  - Patients with significant uncorrected primary valvular disease or uncorrected congenital heart disease; for example, aortic stenosis (AVA <0.8 cm<sup>2</sup>), mitral stenosis (MVA <1.2 cm<sup>2</sup>/m<sup>2</sup>), severe valvular insufficiency requiring valve replacement;
  - 10    • Patients with obstructive cardiomyopathy;
  - Patients with active myocarditis, constrictive pericarditis, untreated hypothyroidism or hyperthyroidism, adrenal insufficiency, active vasculitis due to collagen vascular disease, or other correctable nutritional or metabolic causes for heart failure;
  - 15    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations >3 times the upper limit of normal (ULN) reference range and/or bilirubin ≥2 mg/dL;
  - Patients with significant renal impairment; serum creatinine >2.5 mg/dL or creatinine clearance <30 mL/min;
  - 20    • Serious hematological diseases (e.g., severe anemia, Hgb <10 g/dL:leukopenia, white blood cell [WBC] <4000/ $\mu$ L);
  - Active cancer within 5 years of screening for this study (exclusive of localized skin cancer or localized prostate cancer);
  - 25    • Patients on continuous and/or daily doses of IV inotropic drugs (e.g., dobutamine; dopamine, milrinone, amrinone, etc) or parenteral vasodilators (e.g., nitroprusside; nitroglycerin) within 7 days of screening;
  - Clinical evidence of digitalis toxicity;

-18-

- Current illicit drug use or alcoholism;
- Any concurrent illness which, in the opinion of the investigator, may interfere with treatment, evaluation of safety, and/or efficacy;
- Participation in another clinical trial of an investigational drug (including placebo) within 30 days of screening for entry into the present study; or
- Inability to understand and sign the Informed Consent to participate in this study.

#### **Prohibited/Allowable Medications or Precautions**

To minimize confounding factors and bias in interpreting results related to potential cardiac changes not associated with natural progression of CHF, concurrent heart failure medications should be held stable throughout the treatment phase of the study. Changes in concurrent medications can and should be made where issues of patient safety are evident.

Nonsteroidal anti-inflammatory agents (NSAIDS) are discouraged due to their inhibitory effects on renal function.

Permitted medications include those used to treat coronary artery disease (CAD), hypertension, diabetes, hyperlipidemia, and CHF. Heart failure medications can include ACE inhibitors, diuretics, digoxin,  $\beta$ -blocker, and intermittent oxygen. No other parenteral vasodilators (e.g., nitroprusside, nitroglycerin) nor initiation of inotropic agents will be allowed. Chronic low dose ( $\leq 300$  mg QD) amiodarone is permissible but not sotalol, dofetilide or other Class III antiarrhythmic agents. Calcium channel blockers with negative inotropic effects (e.g., verapamil, diltiazem) are prohibited.

Patients enrolled in this study cannot be participating in any other ongoing protocol studying the effects of investigational medications.

#### **Meals and Fluid Intake**

Patients should fast at least 6 hours prior to baseline hemodynamic measurements and must remain fasting during the first 6 hours of the 12-hour treatment phase.

-19-

Fluid intake will be restricted to 250 mL every 2 hours (except at time of IV infusion of study medication) from time of insertion of Swan-Ganz catheter and throughout the treatment period.

## STUDY METHODOLOGY

### 5 Efficacy Parameters

#### Primary Efficacy Parameter

Peak change from last baseline measurement in PCWP at 3 to 6 hours after start of study medication infusion as compared to placebo. Other characteristics of response profile (area under the PCWP/time curve) are defined in statistical analysis section of the protocol.

#### Secondary Efficacy Parameters

- Peak change from last baseline measurement at 3 to 6 hours after start of study medication infusion as compared to placebo in:
  - Cardiac index (CI)
  - Pulmonary vascular resistance (PVR)
  - Systemic vascular resistance (SVR)
- Other characteristics of response profile (CI, PVR, SVR) are defined in the statistical analysis section of the protocol (area under the curve [AUC]).
- Changes in urine output over time as compared to baseline.
- Descriptive statistics for RA, PAs, PAd, BP, HR will also be performed.
- Change from baseline in numeric rating scale for assessing dyspnea at 12 hours after administration of study medication.

### Safety Assessments

- Hemodynamic Parameters: Boundary values for reduced cardiovascular performance are (expressed as changes from baseline demonstrated on 2 successive readings  $\geq$ 30 minutes apart): (a)  $>25\%$  decrease in CI from baseline; (b)  $\geq 6$  mmHg rise in PCWP above baseline; and (c) systolic arterial BP (SBP)  $<80$  mmHg or  $>10$  mmHg fall in SBP associated with presyncopal symptoms;

-20-

- Changes in serum electrolytes;
  - Clinical laboratory measures including renal function (BUN and creatinine), liver function tests (ALT, AST, Alk Phos, bilirubin), hematological parameters (WBC, neutrophils);
- 5     • Adverse events;
- Changes in urine output over time.

#### Pharmacokinetic/Pharmacodynamic Analysis

Plasma concentrations of YM087 will be measured at 1, 3, and 8 hours after start of IV infusion of study medication using a validated LC/MS/MS method. Assay sensitivity, specificity, linearity, and reproducibility will be determined before analysis of samples.

The relationship between the primary efficacy parameters and plasma concentrations of YM087 including the interindividual variability will be evaluated using appropriate pharmacostatistical methods.

15    Neurohormonal Assessments

Vasopressin plasma levels will be measured at baseline and 12 hours after start of IV infusion of study medication using standard methods.

#### **Dosing Procedure**

YM087 sterile injection will be added to a 50-mL bag containing D5W. Table 2 specifies the amount of YM087 for injection to dilute into D5W in order to achieve the desired dose. The contents of the bag will be administered to the patients via a pump infusion system (e.g., IMED™, IVACT™) over 30 minutes.

**TABLE 2. YM087 Dose Administration**

Dose (mg)	Volume of YM087 (mL)	Volume of D5W added (mL)	Total Volume in Bag (mL)	Concentration (mg/mL)	Infusion Rate Over 30 Minutes (mL/min)
10	2	8	60	0.167	2
20	4	6	60	0.333	2

-21-

40            8            2            60            0.667            2

---

## STATISTICAL ANALYSIS AND RATIONALE

### Power and Sample Size

For this study, a total of 140 patients will be considered with 35 patients in each of the 4 treatment groups (placebo, 10, 20, and 40 mg). The power to detect a difference of 3 mmHg in the PCWP peak change from baseline within 3 to 5 hours after treatment administration, between placebo and any of the 3 active treatments, was determined using the formula for the power of the t-test. Adjustment for multiple comparisons with placebo was performed using Dunnett's approach (Dunnett, *Biometrics*, 1964;20:482-491). Assuming a 15% 10 dropout rate, an overall error rate of 0.05 two-sided, and a standard deviation of 3 mmHg for the PCWP peak change, the power to detect a difference of 3 mmHg between placebo and any of the YM087 groups is 93.6%. However, if a standard deviation of 4 mmHg is assumed, the power becomes 71.1%.

### Efficacy Parameters

15 Hemodynamic data in clinical trials of congestive heart failure is usually assessed by evaluating the differences in change from baseline to peak response among treatment groups. Generally, peak response is defined as an average of measurements taken at prespecified hours (e.g., at 2, 3, and 4 hours).

20 For this study, hemodynamic efficacy parameters of PCWP, CI, SVR, and PVR will be evaluated in terms of their response profile. The response profile will be assessed in terms of peak change, and AUC delimited by the parameter change from baseline and measurement times. The peak change is defined as the maximum change from baseline, within the 3 to 6 hours after treatment 25 administration, in the hemodynamic parameter of interest. The baseline value is considered the last acceptable measurement taken before treatment administration. The AUC will be determined using the "linear trapezoidal rule", by which areas of each trapezoid delimited by: 2 points on the graph of change from baseline against time, perpendiculars from the points to the X-axis, and the X-axis are summed up to get AUC. If measurements are missing at certain times, the AUC will be

-22-

calculated using all other available observations. Dose response over the treatment groups will be assessed for selected measures.

5       The primary efficacy parameter for this study is peak change from baseline in PCWP. The secondary parameters are peak change from baseline in CI, SVR, and PVR. Changes in RA and PA pressures also will be characterized. In addition, changes in urine output will be characterized.

Analysis of the Primary Efficacy Parameter

10      An analysis of covariance (ANCOVA) model will be used as the primary analysis to compare each of the YM087 doses with placebo in terms of peak change in PCWP. The model will include effects due to treatment, center, an indicator variable for the presence or absence of  $\beta$ -blocker therapy, and possibly the baseline value as a covariate. Treatment-by-center and treatment-by-baseline interactions will be investigated. All randomized patients that have a baseline measurement and at least one follow-up measurement will be considered for this analysis. If there is only one observation within 3 to 6 hours then the peak change will be calculated using that observation and the baseline value. If there are no measurements in the 3 to 6 hour window, the last measurement prior to hour 3 will be carried forward and used to calculate peak.

15      A secondary analysis of the AUC will be conducted to support the primary analysis. For the area under the PCWP change from baseline and time curve, the analysis will be conducted using ANCOVA in a similar manner as described for the primary analysis. The model will include effects due to treatment, center, an indicator variable for the presence or absence of  $\beta$ -blocker therapy, and possibly the baseline value as a covariate. Treatment-by-center and treatment-by-baseline interactions will be investigated. All randomized patients that have a baseline and at least one follow-up measurement will be considered for this analysis.

20      In order to claim positivity, results from the primary analysis for peak change in PCWP should be significant at the  $\alpha$  level corresponding to 0.049 using Dunnett's approach, or results from the secondary analysis of AUC at the 0.001 level. A supportive secondary trend analysis for dose response will also be performed. Also, repeated measures ANCOVA will be performed for selected 25 measurements of the response profile.

Analysis of the Secondary Efficacy Parameters

The primary analysis for the secondary efficacy parameters of CI, SVR, and PVR will be performed using ANCOVA as described for the primary efficacy parameter, to compare the treatment groups with placebo in terms of their peak change from baseline. Patients will be considered for this analysis according to the criteria described for the primary parameter. The significance levels will be adjusted for multiple comparisons with placebo using Dunnett's method.

Analysis of the AUC and trend analysis will be considered supportive, and conducted in the same manner as described for the primary parameter. Repeated measures ANCOVA will be performed for selected measurements of the response profile. All randomized patients with a baseline and at least one follow-up measurement will be considered.

The secondary parameter of urine output will be summarized at baseline, and each collection time. In addition, a numeric rating scale will be used for assessing dyspnea. The corresponding change from baseline for these parameters will be summarized. Descriptive summaries will include mean, standard error, median, minimum, and maximum. Other concurrently measured hemodynamic parameters (i.e., RA, PAs, PAd, cuff SBP, cuff DBP, calculated MAP, and HR) will also be summarized.

The results of the foregoing study establish that conivaptan has a surprisingly favorable hemodynamic effect as an add-on therapy to normal treatment with ACE inhibitors. Eighty-five percent of the patients in this study were treated with ACE inhibitors (plus conivaptan). As shown in Figure 1, conivaptan caused significant reductions in PCWP. Figure 2 shows that conivaptan caused a significant reduction in RAP.

The compositions to be employed in the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms for treating and preventing heart failure and ventricular dilation. The compounds can be administered by injection, that is, intra-venously, intramuscularly, intracutaneously, subcutaneously, submucosally, intraductally, intraduodenally, or intraperitoneally. Also, the compounds can be administered by inhalation, for example, intranasally. Additionally, the compositions can be administered transdermally. It will be obvious to those skilled in the art that the following

-24-

dosage forms may comprise as the active component, either a compound as a free base, acid, or a corresponding pharmaceutically acceptable salt of such compound. The active compound generally is present in a concentration of about 5% to about 95% by weight of the formulation.

5       For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, 10 or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

15      In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

20      The powders and tablets preferably contain from 5% or 10% to about 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and 25 lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

30      For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection,

-25-

liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and  
5 thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

10 Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners,  
15 solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as  
20 packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

25 The quantity of each active component in a unit-dose preparation may be varied or adjusted from 1 to 1000 mg, preferably 10 to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

The following examples illustrate typical formulations that can be utilized in the invention.

-26-

Tablet Formulation

Ingredient	Amount (mg)
Conivaptan	25
Quinapril hydrochloride	20
Lactose	30
Cornstarch (for mix)	10
Cornstarch (paste)	10
Magnesium stearate (1%)	5
Total	100

5

The conivaptan, ACE inhibitor, lactose, and cornstarch (for mix) are blended to uniformity. The cornstarch (for paste) is suspended in 200 mL of water and heated with stirring to form a paste. The paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are lubricated with the 1% magnesium stearate and pressed into a tablet. Such tablets can be administered to a human from one to four times a day for treatment of CHF.

Preparation for Oral Solution

Ingredient	Amount
YM-471	400 mg
Quinapril	20 mg
Sorbitol solution (70% N.F.)	40 mL
Sodium benzoate	20 mg
Saccharin	5 mg
Red dye	10 mg
Cherry flavor	20 mg
Distilled water q.s.	100 mL

10

The sorbitol solution is added to 40 mL of distilled water, and the vasopressin antagonist and ACE inhibitor are dissolved therein. The saccharin,

-27-

sodium benzoate, flavor, and dye are added and dissolved. The volume is adjusted to 100 mL with distilled water. Each milliliter of syrup contains 4 mg of invention composition.

PARENTERAL SOLUTION


- 5        In a solution of 700 mL of propylene glycol and 200 mL of water for injection is suspended 20 g of vasopressin antagonist OPC-31260 and 5 g of enalaprilat. After suspension is complete, the pH is adjusted to 6.5 with 1N sodium hydroxide, and the volume is made up to 1000 mL with water for injection. The formulation is sterilized, filled into 5.0 mL ampoules each  
10      containing 2.0 mL, and sealed under nitrogen.

-28-

CLAIMS

What is claimed is:

1. A pharmaceutical composition comprising an effective amount of an angiotensin-converting enzyme inhibitor and an effective amount of a vasopressin antagonist.  
5
2. A composition according to Claim 1 employing an ACE inhibitor selected from captopril, enalapril, enalaprilat, lisinopril, ramipril, zofenopril, trandolapril, temocapril, ceranapril, alacepril, delapril, pentopril, quinapril, quinaprilat, moexipril, rentiaprile, duinapril, spirapril, cilazapril, perindopril, and fosinopril.  
10
3. A composition according to Claim 1 employing a vasopressin antagonist of Formula I



wherein R and R<sup>5</sup> are hydrogen or lower alkyl;

15 R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> independently are hydrogen, halo, lower alkyl, lower alkoxy, amino, alkylamino, or dialkylamino; and  
R<sup>4</sup> is hydrogen, phenyl or substituted phenyl, and pharmaceutically acceptable salts thereof.


-29-

4. A composition according to Claim 3 in which the vasopressin antagonist is conivaptan.
5. A composition according to Claim 2 comprising an ACE inhibitor selected from quinapril hydrochloride, ramipril, enalapril, or moexipril.
- 5 6. A composition according to Claim 5 comprising a vasopressin antagonist selected from conivaptan or a salt thereof.
7. A composition comprising conivaptan and quinapril.
8. A method for treating ventricular dilation, and/or heart failure in a mammal comprising administering an effective amount of a combination of at least one angiotensin-converting enzyme inhibitor and at least one vasopressin antagonist.

10

**THIS PAGE BLANK (USPTO)**


FIG. 1 Change from Baseline in PCWP



**THIS PAGE BLANK (USPTO)**

2/2

FIG. 2 Change from baseline in RAP



**THIS PAGE BLANK (USPTO)**

**INTERNATIONAL SEARCH REPORT**

International Application No

PCT/US 00/32569

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>			
IPC 7	A61K45/06	A61K31/55	A61K38/55
A61P9/00			

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 205 334 A (E.R.SQUIBB & SONS) 17 December 1986 (1986-12-17) claim 1 page 4, line 9-13 page 4, line 33 -page 5, line 4	1,2,8
X	EP 0 344 995 A (E.R.SQUIBB & SONS) 6 December 1989 (1989-12-06) claims 1,6,11	1,2
X	EP 0 365 134 A (SMITHKLINE BEECHAM) 25 April 1990 (1990-04-25) claim 1 page 5, line 5-15	1,2,8
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

- \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed Invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*g\* document member of the same patent family

Date of the actual completion of the International search

1 October 2001

Date of mailing of the International search report

09/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax (+31-70) 340-3016

Authorized officer

Peeters, J

## INTERNATIONAL SEARCH REPORT

ational Application No  
PCT/US 00/32569

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 229 329 A (E.R.SQUIBB & SONS) 22 July 1987 (1987-07-22) claim 1 page 4, line 14-22 page 5, line 4-11 _____	1, 2, 8

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

tional Application No

PCT/US 00/32569

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 205334	A	17-12-1986	AU AU CA DK EP HU JP JP JP NZ US ZA	592344 B2 5837886 A 1271747 A1 272686 A 0205334 A2 47084 A2 1959057 C 6086434 B 61286367 A 216416 A 4748239 A 8604161 A		11-01-1990 18-12-1986 17-07-1990 13-12-1986 17-12-1986 30-01-1989 10-08-1995 02-11-1994 16-12-1986 06-01-1989 31-05-1988 25-02-1987
EP 344995	A	06-12-1989	AU AU DK EP HU JP US ZA	607612 B2 3493089 A 265789 A 0344995 A2 58521 A2 2025422 A 5037821 A 8903735 A		07-03-1991 07-12-1989 02-12-1989 06-12-1989 30-03-1992 26-01-1990 06-08-1991 28-02-1990
EP 365134	A	25-04-1990	EP JP	0365134 A1 2121925 A		25-04-1990 09-05-1990
EP 229329	A	22-07-1987	AT AU AU CA CA CN CZ DD DD DE DE DK EP ES FI HU HU IE IL JP JP KR NO NZ PH PL PT SU ZA SU US	92047 T 591726 B2 6530386 A 1271748 A1 1294617 A2 86108530 A ,B 8609154 A3 258807 A5 270071 A5 3688788 A1 3688788 T2 595686 A ,B, 0229329 A1 2058059 T3 865056 A ,B, 43572 A2 199806 B 61757 B 95607 A 6086435 B 62164668 A 9001177 B1 865012 A ,B, 218292 A 25223 A 271723 A1 83917 A ,B 1790575 A3 8608598 A 1542414 A3 4752645 A		15-08-1993 14-12-1989 18-06-1987 17-07-1990 21-01-1992 17-06-1987 19-01-1994 03-08-1988 19-07-1989 02-09-1993 03-03-1994 13-06-1987 22-07-1987 01-11-1994 13-06-1987 30-11-1987 28-03-1990 30-11-1994 25-05-1992 02-11-1994 21-07-1987 27-02-1990 15-06-1987 28-10-1988 27-03-1991 08-12-1988 01-01-1987 23-01-1993 24-06-1987 07-02-1990 21-06-1988

**THIS PAGE BLANK (USPTO)**